Valerion Therapeutics said today that the company developed a fusion protein, VAL-1221, that combines its antibody delivery system with recombinant human acid alpha-glucosidase (rhGAA) to better deliver rhGAA into affected tissues of patients with Pompe disease. Patients who suffer from Pompe disease have a deficient supply of the lysosomal enzyme, GAA, which causes glycogen to […]
